Antimicrobial activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria

Objectives: To evaluate in vitro activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria (NFGNB). Methods: The isolates of less common NFGNB were collected during a long period spanning five years from 2016 to 2020 in Huashan Hospital, Fudan University in Shanghai. A broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of sitafloxacin and comparators. Results: In terms of MIC 50/90 values, sitafloxacin was highly active against Stenotrophomonas maltophilia (0.25/1 mg/L), Burkholderia cepacia complex (0.25/2 mg/L), Achromobacter xylosoxidans (0.25/1 mg/L), and Chryseobacterium gleum (1/2 mg/L), but less active for Elizabethkingia (1/8 mg/L) and Chryseobacterium indologenes (16/32 mg/L). Sitafloxacin was more active than other fluoroquinolones against these NFGNB except Chryseobacterium . Conclusion: The results are helpful for clinicians to be aware of the role of sitafloxacin in managing the infections caused by these NFGNB.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Automated summary

This study evaluated the in vitro activity of sitafloxacin against less common nonfermenting Gram-negative bacteria (NFGNB). Sitafloxacin demonstrated high activity against Stenotrophomonas maltophilia, Burkholderia cepacia complex, Achromobacter xylosoxidans, and Chryseobacterium gleum. These findings provide valuable guidance for clinicians in selecting appropriate antimicrobial agents for infections caused by these bacteria.